MY140005A - Novel ligands and methods for preparing same - Google Patents
Novel ligands and methods for preparing sameInfo
- Publication number
- MY140005A MY140005A MYPI20071700A MYPI20071700A MY140005A MY 140005 A MY140005 A MY 140005A MY PI20071700 A MYPI20071700 A MY PI20071700A MY PI20071700 A MYPI20071700 A MY PI20071700A MY 140005 A MY140005 A MY 140005A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- preparing same
- novel ligands
- parent ligand
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
A PROCESS IS DISCLOSED FOR MODIFYING A PARENT LIGAND BY ATTACHING TO THE PARENT LIGAND A CONJUGATION AGENT THAT IS REACTIVE WITH A MOLETY OF A TARGET RECEPTOR TO WHICH THE PARENT LIGAND BINDS SUCH THAT A COVALENT BOND IS FORMABLE BETWEEN THE CONJUGATION AGENT AND THE REDEPTOR MOIETY. ALSO DISCLOSED ARE COMPOSITIONS, PROBES AND METHODS OF DETECTING AND/OR QUANTIFYING RECEPTORS USING THE MODIFIED LIGANDS OF THE INVENTION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17875600P | 2000-01-28 | 2000-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY140005A true MY140005A (en) | 2009-11-30 |
Family
ID=22653836
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20010368A MY137705A (en) | 2000-01-28 | 2001-01-29 | Novel ligands and methods for preparing same |
MYPI20071700A MY140005A (en) | 2000-01-28 | 2001-01-29 | Novel ligands and methods for preparing same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20010368A MY137705A (en) | 2000-01-28 | 2001-01-29 | Novel ligands and methods for preparing same |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1289561A2 (en) |
JP (1) | JP2003529560A (en) |
KR (1) | KR20020082218A (en) |
CN (1) | CN1418111A (en) |
AU (2) | AU2001234020C1 (en) |
CA (1) | CA2398435A1 (en) |
IL (1) | IL150890A0 (en) |
MY (2) | MY137705A (en) |
SG (1) | SG148022A1 (en) |
WO (1) | WO2001054731A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2141166A1 (en) * | 2008-06-30 | 2010-01-06 | Rheinische Friedrich-Wilhelms-Universität Bonn | Adenine receptor ligands |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
US20220275019A1 (en) * | 2021-02-27 | 2022-09-01 | Agilent Technologies, Inc. | Hydrocinnamoyl protected riboguanosine phosphoramidites for decreasing depyrimidination from alkyl amine exposure during final deprotection |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US367058A (en) * | 1887-07-26 | Meadow-planer | ||
US4981979A (en) * | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
US5298508A (en) * | 1988-07-19 | 1994-03-29 | The United States Of America As Represented By The Department Of Health And Human Services | Irreversible inhibitors of adenosine receptors |
US5134071A (en) * | 1989-02-06 | 1992-07-28 | State University Of New York | Polymerization and copolymerization of proteins |
GB8907310D0 (en) * | 1989-03-31 | 1989-05-17 | Medical Res Council | Heteroconjugates |
ES2085920T3 (en) * | 1989-06-23 | 1996-06-16 | Liposome Co Inc | TARGETED LIPOSOMES AND LIPOSOMA-PROTEIN COUPLING METHODS. |
DE4014540A1 (en) * | 1990-05-07 | 1991-11-14 | Klaus Dr Tschaikowsky | Immune conjugates for prophylaxis and treatment of organ damage - caused by inflammation, esp. sepsis, contain monoclonal antibody, crosslinker and enzyme inhibitor of protein kinase C or calcium antagonist |
IE914220A1 (en) * | 1990-12-10 | 1992-06-17 | Akzo Nv | Labelled, modified oligonucleotides |
US5329028A (en) * | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
JP2000500120A (en) * | 1995-09-21 | 2000-01-11 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | Targeting of conjugate of poly (ethylene glycol) and anti-glutamate decarboxylase antibody to pancreatic islet cells |
AU1039397A (en) * | 1995-11-22 | 1997-06-27 | Johns Hopkins University, The | Ligands to enhance cellular uptake of biomolecules |
-
2001
- 2001-01-26 IL IL15089001A patent/IL150890A0/en unknown
- 2001-01-26 AU AU2001234020A patent/AU2001234020C1/en not_active Ceased
- 2001-01-26 EP EP01906058A patent/EP1289561A2/en not_active Withdrawn
- 2001-01-26 CA CA002398435A patent/CA2398435A1/en not_active Abandoned
- 2001-01-26 WO PCT/IB2001/000293 patent/WO2001054731A2/en active IP Right Grant
- 2001-01-26 SG SG200404069-7A patent/SG148022A1/en unknown
- 2001-01-26 KR KR1020027009755A patent/KR20020082218A/en not_active Application Discontinuation
- 2001-01-26 JP JP2001554714A patent/JP2003529560A/en not_active Withdrawn
- 2001-01-26 CN CN01805651A patent/CN1418111A/en active Pending
- 2001-01-29 MY MYPI20010368A patent/MY137705A/en unknown
- 2001-01-29 MY MYPI20071700A patent/MY140005A/en unknown
- 2001-03-05 AU AU3402001A patent/AU3402001A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1418111A (en) | 2003-05-14 |
AU3402001A (en) | 2001-08-07 |
IL150890A0 (en) | 2003-02-12 |
SG148022A1 (en) | 2008-12-31 |
AU2001234020C1 (en) | 2006-08-10 |
CA2398435A1 (en) | 2001-08-02 |
EP1289561A2 (en) | 2003-03-12 |
WO2001054731A2 (en) | 2001-08-02 |
JP2003529560A (en) | 2003-10-07 |
MY137705A (en) | 2009-02-27 |
KR20020082218A (en) | 2002-10-30 |
WO2001054731A3 (en) | 2002-12-12 |
AU2001234020B2 (en) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021142377A3 (en) | Cell surface receptor binding compounds and conjugates | |
NZ609752A (en) | Process for preparing maytansinoid antibody conjugates | |
EP1124568A4 (en) | Polyspecific binding molecules and uses thereof | |
SG151261A1 (en) | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination | |
EA200601670A1 (en) | Conjugates of hydroxyalkyl starch and protein | |
CN105473618A (en) | Anti-fcrh5 antibodies | |
MXPA03008218A (en) | Conjugate of hydroxyalkyl starch and an active agent. | |
WO2000073796A3 (en) | Ligand-anchor conjugates for producing a biosensor layer | |
DK1258497T3 (en) | Process for Preparation of Factor VIII Conjugates and a Biocompatible Polymer | |
DE3773237D1 (en) | A MACROCYCLIC COORDINATE AND AN ANTIBODY-CONJUGATE COMPOUND. | |
WO2002043771A3 (en) | Conjugates of glycosylated/galactosylated peptide | |
DE60133479D1 (en) | MODIFIED TPO AGONISTS ANTIBODIES | |
BR9812376A (en) | Use of a nucleoside pentopyranosyl for the production of an electronic component, and its conjugates | |
MA33701B1 (en) | ANTIBODIES THAT BIND SPECIFICALLY TO THE EPHA2 RECEIVER | |
NZ583894A (en) | Antibodies that bind to a non atp binding p2x7 receptor | |
DK1053355T3 (en) | PNA and DNA conjugates and methods for their preparation | |
MX2023008339A (en) | Camptothecine antibody-drug conjugates and methods of use thereof. | |
MY137705A (en) | Novel ligands and methods for preparing same | |
WO2007058725A3 (en) | Engineered antibody fragment that irreversibly binds an antigen | |
WO2022150721A9 (en) | Bifunctional folate receptor binding compounds | |
BR0316355A (en) | Imidazoquinoline derivatives as a3 adenosine receptor ligands | |
WO2006079099A3 (en) | Method of conjugating aminothiol containing molecules to a polymer | |
CA2365385A1 (en) | Use of 13c-nmr to detect binding | |
MX2010006910A (en) | Selective radiolabeling of biomolecules. | |
WO2004087059A3 (en) | Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding |